7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A critical appraisal of the OASIS-1 trial for oral semaglutide 50 mg, covering enrollment biases, generalizability gaps, statistical caveats, sponsor involvement, and post-publication commentary.
A detailed breakdown of the OASIS-1 trial design, randomization, estimand framework, and statistical choices that produced the 15.1% weight-loss result for oral semaglutide 50 mg.
Deep dive into OASIS-1 trial follow-up and extension data for oral semaglutide 50 mg, covering weight regain patterns, durability of effect, and long-term safety signals beyond 68 weeks.
A full breakdown of OASIS-1's primary and secondary endpoints, confidence intervals, time-course weight loss pattern, and response distribution for oral semaglutide 50 mg at 68 weeks.
A deep dive into the pre-specified and post-hoc subgroup analyses from OASIS-1, examining how age, sex, BMI, baseline biomarkers, and race/ethnicity shaped weight-loss response to oral semaglutide 50 mg.
A deep-dive overview of the OASIS-1 trial, the first randomized controlled trial testing oral semaglutide 50 mg for weight loss, reporting 15.1% body weight reduction at 68 weeks.
How the OASIS-1 trial of oral semaglutide 50 mg reshapes obesity treatment guidelines, prescribing patterns, and patient selection beyond the abstract results.